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1. Introduction
Articular cartilage has a function to smooth the movement of the joints and to decrease the
coefficient of friction. Recently, it has been reported that “lubricin,” a mucinous glycoprotein
encoded by the PRG4 gene, provides boundary lubrication in the articular joints [1]. Also, the
articular cartilage has a role of shock absorber against an external force. The articular cartilage
is hyaline cartilage composed of water (approximately 70%), cell (less than 3%), and abundant
extracellular matrix (approximately 20%) such as type II collagen and proteoglycan. The
articular cartilage is highly differentiated avascular tissue, and blood vessels, nerves, and
lymphatic vessels are not present in the articular cartilage of adults. Based on the above, it is
well known that damaged articular cartilage has a very limited capacity for self-repair. Even
minor injuries may lead to progressive damage and result in osteoarthritic joint with significant
pain and disability.
In 1989, it was reported that cartilage defect could be repaired with cultured chondrocytes in
animal experiments in rabbits [2]. Based on this result, Brittberg et al. [3] performed clinical
application for humans of autologous chondrocyte transplantation in 1994. However, some
problems have been pointed out in this surgery. One was the possibility of dedifferentiated of
cultured cells, which decreased matrix production ability because of monolayer culture.
Another was the uneven distribution of injected chondrocytes caused in part by leak of the
cell suspension from the periosteum covering the cartilage defect. To solve these problems,
Ochi et al. [4] devised the use of atelocollagen as a scaffold: implantation of three-dimensional
cartilage-like tissues using cultured autologous chondrocytes embedded in atelocollagen gel.
This method has been currently used as a clinical application for osteochondritis dissecans
since 2012 [5]. However, there is yet no clinically approved cell-based strategy for treatment
of osteoarthritis (OA)-based cartilage lesions. Basic researchers and clinicians are focusing on
alternative methods for cartilage repair, aiming to regenerate OA cartilage tissues. Cell-based
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therapy is an attractive biological method, and its studies have progressed in accordance with
the development of tissue engineering.
2. Cell-based therapy for OA
Cell-based therapies using various cell types such as the chondrocytes or the bone marrow
have been researched conventionally. Autologous chondrocytes are actually in clinical
application for cartilage defects, and the surgical procedures such as marrow stimulation have
also been performed for the purpose of cartilage repair. Although short-term results of these
methods are good, there remains in doubt about long-term results. Mesenchymal stem cells
(MSCs) are harvested from different sources such as the bone marrow, synovial tissue, and
adipose tissue and have multilineage potentials. Recently, research in cartilage tissue engi‐
neering focuses on the use of MSCs as an alternative to autologous chondrocytes. Furthermore,
induced pluripotent stem (iPS) cells or Muse cells might overcome the disadvantages of MSCs:
insufficient number of cells, cell harvesting procedures with pain, and unstable differentiation
potential of cells.
The regeneration of hyaline cartilage provides to improve the symptoms and ultimately
prevent or delay progression to osteoarthritic joints. Cell-based therapies have been increas‐
ingly applied because they have the potential to regenerate the cartilage tissues.
2.1. Chondrocyte
2.1.1. Autologous chondrocyte implantation
Autologous chondrocyte implantation (ACI) was first reported in 1994 for treatment of focal
cartilage defects in the tibiofemoral and patellofemoral compartments [3]. Since this report,
chondrocyte-based therapy has become to be expected; a periosteal cover (first-generation
ACI), a collagen-membrane cover (second -generation ACI), and a variety of three-dimensional
scaffolds (third-generation ACI) are used for the methods of fixation. In these methods,
arthrotomy and a two-stage surgical procedure are used. Long-term durability and success as
long as 11 years of follow-up periods have been reported [6–13]. ACI is the first articular
cartilage repair method using tissue engineering, but there is a problem that a sufficient
number of cells cannot be secured by the case. Its usefulness is still under discussion.
2.1.2. Matrix-induced autologous chondrocyte implantation
A variation of the original periosteum membrane technique is matrix-induced autologous
chondrocyte implantation (MACI). MACI membrane consists of a porcine type I/III collagen
bilayer seeded with chondrocytes and MACI can promote hyaline-like cartilage repair. The
technique of MACI procedure can eliminate many problems of first- or second-generation ACI,
and the cell-seeded membrane can be implanted over a less inaccessible area or at osteochon‐
dral junctions because of its adhesive property [14]. Meyerkort et al. reported that both MACI
and tibial tubercle transfer (TTT) using the Fulkerson technique were used to treat cartilage
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defects in the patellofemoral joints and provided a durable graft on 5-years resultant with
clinical improvement [15–17].
2.2. Bone marrow
Marrow stimulation techniques such as abrasion arthroplasty, drilling, and microfracture
penetrate the subchondral bone and induce the formation of fibrocartilage repair tissues [18].
Although these methods were performed traditionally, it has been shown recently that
bleeding from the bone marrow resulted in the supply of cytokines, osteoprogenitor cells, and
chondroprogenitor cells. Also, there have been many reports related to induction of MSCs by
bone marrow stimulation techniques. Clinically, although excellent short-term outcomes have
been reported after bone marrow stimulation, the durability of marrow-stimulated repair
tissues has shown the tendency to functional decline with further follow-up.
2.2.1. Abrasion arthroplasty
In 1986, Johnson [19] reported about achievement of abrasion arthroplasty, removing dead
bone superficially and providing vascularity tissues for blood clot attachment. According to
this method, subsequent fibrocartilage formation was maintained integrity for up to 6 years.
Sansone et al. [20] reported a 20-year follow-up of abrasion arthroplasty, with a positive
functional outcome of 67.9%.
2.2.2. Multiple perforation (drilling)
In 1959, Pridie [21] reported about a method for multiple perforation to subchondral bone
using a drill with a 6-mm diameter. After partial weight bearing for 6 weeks, holes drilled were
filled with fibrocartilage. However, recent reports related to medial opening-wedge high tibial
osteotomy suggest that subchondral drilling is not necessary because there is no significant
difference in the formation of fibrocartilage with or without subchondral drilling [22].
2.2.3. Microfracture
Microfracture is common procedure for cartilage repair, which produces a small fracture of
the subchondral bone using awls to penetrate eburnated bone to promote blood flow to the
bony surface. There is a report that short-term results were good, but 38.1% proceeded to total
knee arthroplasty (TKA) in a 6.8-year follow-up [23]. In other papers, the survival rate was
88.8% at a 5-year follow-up and decreased 67.9% at a 10-year follow-up [24, 25].
2.3. Mesenchymal stem cell
Nucleated cells in the bone marrow are mostly hematological cells, which float when they are
cultured. However, some of the cells in the bone marrow adhere to culture dishes in vitro,
proliferate itself, and form colonies. Thus, adherent cells are regarded as bone marrow
mesenchymal cells (BMMCs). In 1974, Friedenstein et al. [26] reported that osteochondral
progenitor cells were present in BMMCs, and in 1999, Pittenger et al. [27] reported about the
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pluripotency of BMMCs, named MSCs. Currently, it is well known that MSCs are adult stem
cells and have the possibility of differentiating into multiple cell types, including adipocytes,
chondrocytes, osteocytes, and cardiomyocytes [28].
2.3.1. Bone marrow MSC
Articular cartilage is insufficient for the capacity of cartilage repair, and the damaged cartilage
tissues are not restored in complete hyaline cartilage in adults. We reasoned that the chon‐
droprogenitor cells supplied to the cartilage defects are not sufficient. Then we have focused
on the BMMCs, which might include MSCs, to supply sufficient chondroprogenitor cells to
cartilage defects [29]. In our study in rabbits, BMMCs, which had a fibroblastic morphology
and pluripotency for differentiation, were isolated from the bone marrow of the tibiae of
rabbits, grown in monolayer culture. The autologous cells were then implanted into full-
thickness articular cartilage defects in the knee joints of each rabbit. Advantages of this method
included the use of autologous cells and absence of immunoreactivity. Furthermore, we
investigated the efficiency of cartilage-derived morphogenetic protein 1 (CDMP1) gene-
transfected autologous BMMCs for cartilage repair in a rabbit cartilage defect model [30].
CDMP1, a member of the transforming growth factor-β superfamily, is an essential molecule
for the aggregation of mesenchymal cells and acceleration of chondrogenic differentiation.
BMMCs were isolated from the bone marrow of the tibiae of rabbits, grown in monolayer
culture, and transfected with the CDMP1 gene or a control gene (GFP) by a lipofection method.
During in vivo repair of full-thickness articular cartilage defects, cartilage regeneration was
enhanced by the implantation of CDMP1-transfected autologous BMMCs (Figure 1). The
defects were filled with hyaline cartilage, and the deeper zone showed remodeling to sub‐
chondral bone over time. The repair and the reconstitution of zones of hyaline articular
cartilage were superior to simple BMMC implantation. The histological score of the CDMP1-
transfected BMMC group was significantly better than those of both control BMMC group and
empty control group (Tables 1 and 2). Our studies suggest that the modulation of BMMCs by
factors such as CDMP1 allows enhanced repair and remodeling compatible with hyaline
articular cartilage.
2.3.2. Synovial MSC
Sekiya et al. [31] previously reported that MSCs in synovial fluid from anterior cruciate
ligament injury, meniscus injury, or patients with OA were much more than those from healthy
volunteers and increased according to postinjury period or severity. The MSCs in synovial
fluid are considered to be derived from synovial tissue and are positive for CD44, CD73, and
CD90, which are markers of MSCs, and negative for CD34 and CD45, which is a marker of
hematopoietic stem cells and leukocyte progenitor cells, respectively. Intra-articular injection
of the synovial MSCs promoted meniscus regeneration and protected articular cartilage by
arthroscopic and histological observations in pig [32], rat [33], or porcine [34] massive meniscal
defect models. We research for synovial fluid cells that are not accompanied by pain in the cell
harvest and describe about its advantage in the latter part of this manuscript.
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Figure 1. Representative histological appearance of the defects after 4 weeks. (A–J) Safranin-O/fast green staining. (A–
C) Empty control group. (D–F) Left knees of GFP-transfected BMMC group. (G–I) Right knees of CDMP1-transfected
BMMC group. (D and G, E and H, F and I) Bilateral knee specimens from the same rabbits. (J) Higher magnification of
I. (K) Immunohistochemical staining specific for type II collagen. (L) Immunohistochemical staining specific for type I
collagen. (A–L) Scale bar is 500 μm.
2.3.3. Adipose-derived MSC
Adipose tissues contain various cells such as blood cells, endothelial cells, and smooth muscle
cells, in addition to adipocytes. Adipose tissues are also rich in microvasculature which adjoins
with MSCs. Adipose-derived MSCs (ASCs) can be established by following method. Subcu‐
taneous or visceral adipose tissues are minced and treated with type I collagenase. Then
infranatant cells are centrifuged at low speed, and the cell pellet is placed in a flask. ASCs
propagate themselves rapidly. Currently, two clinical trials for humans, which are the intra-
articular injection for OA in France and the intravenous administration to rheumatoid arthritis
in Spain, have been undergoing.
2.4. Induced pluripotent stem cells
iPS cells have pluripotency and the potential for self-renewal similar to ES cells. Recent study
has made it possible to generate integration-free iPS cells and to differentiate iPS cells toward
chondrocytes [35]. As an alternative approach, chondrocytic cells can be induced directly from
dermal fibroblasts without going through the iPS cell stage. In 2011, Hiramatsu et al. [35]
generated in vitro polygonal chondrogenic cells from adult dermal fibroblast cultures by
ectopic expression of reprogramming factors (c-Myc and Klf4) and one chondrogenic factor
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(SOX9). Namely, this approach could lead to the preparation of hyaline cartilage directly from
skin without generating iPS cells. Recently, Yamashita et al. [36] reported that hyaline cartilage
was generated from human iPS cells in immunodeficiency rats and immunosuppressed mini-
pigs.
Total maximum                                        20 
Points 
(Subtotal          13) 
A. Cell morphology   
and Matrix staining   
           
 
 
B. Surface regularity† 
 
                       
 
C. Integration of donor with 
host adjacent cartilage 
0   Hyaline cartilage 
2   Mostly hyaline cartilage 
4   Moderately hyaline cartilage 
6    Partly hyaline cartilage 
8    Fibrous 
0    Smooth (>3/4)   
1   Moderate (>1/2–3/4)   
2    Irregular (>1/4–1/2) 
3    Severely irregular (<1/4) 
0    Both edges integrated 
1   One edge integrated 
2   Neither edge integrated 
Category I 
D. Filling of defect   
           
 
 
 
E. Reconstitution of 
subchondral bone and   
osseous connection 
0    ~100%   
1    ~75%   
2    ~50%   
3    ~25% 
4    0% 
0   Yes   
1   Almost   
2    Partly   
3   Not close 
Category II 
(Subtotal          7) 
*Modified from the scale described by Pineda et al. [46] and Wakitani et al. [47].
†Total smooth area of the reparative cartilage compared with the entire area of the cartilage defect.
Table 1. Histological grading scale for cartilage defect*
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 Interval   
until animals 
were killed 
(weeks) 
No. 
E. 
Reconstitution of   
subchondral bone   
and osseous connection 
D. 
Filling 
of defect
C. 
Integration
B.   
Surface 
regularity
A.   
Cell morphology   
and matrix staining Total
Grade (points)
CDMP1 transfected BMMCs 
2 
4 
8 
10 
10 
10 
2 
4 
8 
10 
10 
10 
6.2 
4.4 
4.6 
2.6 
1.6 
1.9 
1.2
1.1
1.5
1.4
0.9
1.0
1.2
0.9
1.5
0.7# 
0.1# 
    0.3*,# 
0.8
0.7
0.7
1.2
0.7
1.0
  2.6# 
1.5 
1.1 
7.0 
6.2 
6.8 
11.5# 
  7.4# 
    7.8*,# 
13.4   
10.7   
12.7 
GFP transfected BMMCs 
2 
4 
8 
2 
7 
7 
3.0 
1.9 
2.0 
2.5
1.6
1.6
2.0
1.6
1.0
3.0
1.1
1.6
8.0 
6.6 
7.4 
18.5   
12.7   
13.6 
Empty control 
Subtotal
（A–C)
Subtotal
（D–E) 
9.6
8.0
9.3
8.1# 
5.2# 
    6.0*,# 
13.0
9.3
10.0
3.8 
2.7 
3.4 
3.4# 
2.2   
1.8# 
5.5 
3.4 
3.6 
*P < 0.05, when compared to the GFP group at corresponding time (Mann–Whitney U-test).
#P < 0.05, when compared to the empty control at corresponding time (Scheffe test for multiple comparison).
Table 2. Results of the histological grading scale
2.5. Multilineage-differentiating stress enduring (Muse) cell
As a novel type of pluripotent stem cells, Muse cells were recently reported as adult human
MSCs without introducing exogenous genes, and they are present in mesenchymal tissues
such as the bone marrow, adipose tissue, dermis, and connective tissue of organs [37–40]. In
particular, Muse cells have been detected more abundant in adipose tissues than in other
organizations [41]. Also, Muse cells have a low tumor-forming ability compared with embry‐
onic stem (ES) cells and a high efficiency of change to iPS cells by Yamanaka gene introduction
[42]. They can migrate to damaged tissues by intravenous injection in vivo, spontaneously
differentiate into cells compatible with the targeted tissue, and contribute to tissue repair. Thus,
Muse cells will be expected to play important role in regenerative therapy by further studies.
3. MSCs in synovial fluid of human OA
In 2004, Jones et al. [43, 44] reported that the MSCs in synovial fluid in the inflammatory and
degenerative arthritis, including OA, possessed high proliferative potential and could
differentiate into several mesenchymal lineages. Aspiration of synovial fluid in the cases of
hydrarthrosis caused by OA has the following great advantages: extremely simple technique,
feasible during routine practice in outpatients, no need for local or general anesthesia for cell
harvest, and effective usage of synovial fluid supposed to be discarded in the cases of hy‐
drarthrosis.
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3.1. Potential of chondrogenic differentiation of synovial fluid cells
We investigated the possibility of chondrogenic differentiation of the cells derived from
synovial fluid and compared with the BMMCs previously performed in human OA [45].
Synovial fluid was aspirated from 26 knee joints of outpatients with OA and those of six
patients just before skin incision at TKA. Bone marrow was obtained from the femur before
the insertion of the femur rod at the time of TKA. Each aspirated fluid was diluted in α-
modified Eagle’s minimum essential medium (αMEM), and mononuclear cells using Ficoll-
Paque PLUS (GE Healthcare) were harvested and cultured. Primary passage cells were used
for flow cytometry assay and for chondrogenic assay, total RNA was prepared from each pellet
of cultured cells, and pellets were used for immunohistochemical staining.
Figure 2. A, B) Phase-contrast photomicrographs of cultured synovial fluid cells on day 6 (A) and day 28 (B) showing
fibroblast-like morphology. On day 28, the culture dish in subconfluency. (C–E) Multipotency of the cultured synovial
fluid cells. (C) Osteogenesis was shown by alkaline phosphatase staining and the expression of osteopontin messenger
(m) RNA (OPN). (D) Chondrogenesis was shown by toluidine blue staining and the expression of type II collagen
mRNA (Col2a1). (E) Adipogenesis was shown by oil red-O staining and the expression of PPARγ mRNA (PPARγ).
In the results, the morphology of the cultured synovial fluid cells was fibroblastic, similar to
that of BMMCs. Also, the synovial fluid cells had an ability to differentiate into osteoblasts,
chondrocytes and adipocytes (Figure 2). The cultured synovial fluid cells strongly expressed
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CD13, CD44, and CD105 but lacked CD10, CD14, and CD45 in flow cytometry analysis. Both
mRNA expression of aggrecan and type II collagen had an increasing tendency at day 21
compared with day 7. Also, the cell pellets derived from synovial fluid showed intense
toluidine blue staining, indicating chondrogenic differentiation.
3.2. Potential of cartilage regeneration of synovial fluid cells
Synovial fluid was aspirated from the OA knees before 1 month of TKA and cultured in vitro.
Degenerative OA cartilage was obtained at the time of TKA. Approximately 5 × 105 autologous
synovial fluid cells were labeled with Cell Tracker Green (CTG) (Invitrogen) in 200-μL αMEM
and were transplanted gently on macroscopic degenerative tissues of OA cartilage. After10
min, medium was removed and changed into chondrogenic medium. One week later, the
tissues were observed under a fluorescent microscope.
Figure 3. Ex vivo study using synovial fluid cells. (A) The formation of repaired tissue was shown by hematoxylin and
eosin (HE) staining (Black arrows). (B) Magnified feature of A. (C) Repaired tissues and the surroundings of CTG-
stained cells were weakly positive by safranin-O staining. (D) Fluorescent microscopy showed that CTG-labeled syno‐
vial fluid cells existed in repaired cartilage. (E) Magnified feature of D. (F) CTG-positive cells had a tendency to
infiltrate into the original degenerative cartilage (White arrows). N.C.: Negative Control without CTG-labeled cells.
Histopathologically, degenerative tissues with transplanted CTG-labeled cells were weakly
positive by safranin-O staining, which indicated that they were toward cartilage tissues (Figure
3). Fluorescent microscopy showed that CTG-labeled synovial fluid cells existed in the repaired
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tissues, which indicated that the tissues were constructed of autologous transplanted cells and
the synovial fluid cells had a tendency to adhere to the degenerative cartilage. Furthermore,
they seemed to infiltrate into the original degenerative cartilage of OA.
3.3. Cell-based therapy using synovial fluid cells
From previous and our current study, it has been recognized that synovial fluid in OA knee
joints contain the adherent cells, and these cells have a potential of cell proliferation and
chondrogenic differentiation in vitro. The primary culture of the human synovial fluid cells
showed the formation of colonies of fibroblast-like cells, similar to those of BMMCs in both
flow cytometry and real-time PCR analysis [34]. The infiltration of synovial fluid cells into the
degenerative cartilage indicates that the possibility of attachment to OA cartilage in humans
may promote the production of extracellular matrix and regeneration of hyaline cartilage.
Further studies are need, but we expect the benefits of synovial fluid cells on OA cartilage
tissues.
4. Conclusions
Many studies using various cell types for OA treatment are being performed. These short-term
results appear mostly satisfactory, but there remains a problem that repaired tissues become
fibrocartilage thereafter. Fibrocartilage leads to different biomechanical characteristics
compared with hyaline cartilage and progresses to OA. MSCs based on self-repair and
multilineage potentials provide to hyaline cartilage regeneration. In particular, bone marrow-
derived MSCs are the most commonly used cell type for cartilage regeneration, but harvesting
of the bone marrow is a painful procedure and has the risk of wound infection and sepsis.
Alternatively, synovial fluid cells have great advantages and cartilage regeneration potential
similar to bone marrow-derived MSCs. Naturally, long-term studies are needed whether
repaired tissues are durable within the joint, but the use of synovial fluid cells may be expected
to cartilage regeneration for OA therapy.
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